Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Substances for treatment of fatty liver-related conditions

A composition and serine technology, applied in metabolic diseases, drug combination, drug delivery, etc., can solve the problems of limiting drug target identification and biomarker discovery

Active Publication Date: 2019-10-25
SCANDIBIO THERAPEUTICS AB
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The molecular mechanisms underlying the onset of HS and its transition to severe hepatic disorders remain elusive, limiting the identification and development of drug targets that can be used to design effective therapeutic strategies. Biomarker Discovery

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substances for treatment of fatty liver-related conditions
  • Substances for treatment of fatty liver-related conditions
  • Substances for treatment of fatty liver-related conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0180] Experimental procedure

[0181] subjects

[0182] Eighty-six subjects with various degrees of HS were recruited to study the liver response to HS. The clinical characteristics of the subjects are shown in Table 1. In addition, liver tissue samples were collected from 12 morbidly obese subjects who underwent bariatric surgery. The characteristics of the morbidly obese subjects are shown in Table 2. The mRNA expression of the identified target genes was measured in the livers of obese and healthy subjects. To show the effect of serine on the liver, six additional subjects were recruited and the characteristics of the subjects before and after serine supplementation are shown in Table 3. Subjects included in the study met all criteria for NAFLD, including exclusion of other chronic liver diseases such as viral hepatitis, high-risk alcohol consumption (high-risk alcoholism), metabolic disorders (eg, hemochromatosis).

[0183] Table 1 Clinical characteristics of the 86 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

There is provided a composition comprising: A) serine, glycine, betaine, N- acetylglycine, N-acetylserine, dimethylglycine, sarcosine and / or phosphoserine; B) N-acetyl cysteine, cysteine and / or cystine; C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4- trimethylammoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and / or lysine; and D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D- ribonucleotide, nicotinate D-ribonucleoside,nicotinamide and / or nicotinate, wherein the molar ratio of A) to D) is between250:1 and 1.5:1 and the molar ratio of A) to B) is between 16:1 and 1:4. The composition may be used in a method of treatment of a medical condition selected from the group consisting of non-alcoholicfatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), type 2 diabetes, obesity, insulin resistance and dyslipidemia.

Description

technical field [0001] The present invention relates to the treatment of fatty liver disease and related disorders. Background technique [0002] Hepatic steatosis (HS) is defined as the accumulation of fat in the liver in the absence of signs of hepatocellular damage, and it is the most common chronic liver disease in the world (Vetelainen et al., 2007). HS is a feature of nonalcoholic fatty liver disease (NAFLD) and is strongly associated with obesity, insulin resistance, type 2 diabetes (T2D) and cardiovascular disease (Ratziu et al., 2010). Up to 30% of NAFLD subjects suffer from nonalcoholic steatohepatitis (NASH), a serious disease in which inflammation and scarring can eventually lead to cirrhosis and hepatocellular carcinoma (HCC) (Dyson et al. 2014). [0003] The underlying molecular mechanisms leading to the onset of HS and its transition to severe liver disorders remain elusive, limiting the identification of drug targets and the discovery of biomarkers that can...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/455A61K31/198A61K31/205A61K9/08A61K31/675A61P1/16A61P3/04A61P3/06
CPCA61K9/08A61K31/198A61K31/205A61K31/455A61K31/675A61P1/16A61P3/06A61P3/04A61K9/0095A61K9/10A61K2300/00A61P3/10A61K31/706
Inventor 阿迪尔·马尔蒂诺格鲁扬·博伦马蒂亚斯·乌伦
Owner SCANDIBIO THERAPEUTICS AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com